NOSA microbial control
NOSA microbial control is designed to reduce the exposure of viruses and bacteria by inhalation through the nose. The product is easy to breathe through, discreet and comfortable to wear.
The nose and upper respiratory tract consist of a sensitive mucous membrane that also passes into our olfactory system (odor receptors). Viruses and bacteria can enter the body and infect us through these sensitive areas. A reduced exposure to viruses and bacteria in the nose has been shown to reduce the risk of becoming infected and ill.
Reduces the exposure of viruses and bacteria:
93% viral reduction
99% bacterial reduction
How does NOSA microbial control work?
NOSA microbial control is placed in the nostrils so that you can breathe through the product. The product design forces the air to pass through the device where the virus and bacteria gets in contact with the lamella structure that captures and inactivates the microbials. This is possible due to the unique silver ion substrate inside the lamellae structure.
In this way, the device reduces the amount of viruses and bacteria that enters the respiratory system. NOSA microbial control is a medical device class 1 and is available within Europe.
The common entry point for virus and bacteria
Most respiratory infections are spread through droplet infection that reaches the mucous membranes of the individual directly through the air, or first through the hands which then come in contact with sensitive mucous membranes. Droplet infections are small drops of liquid that for example come from sneezing or coughing, which fall into the air around the environment of the individual.¹
Face masks as virus and bacteria protection
There are several different face masks with different purposes. These are usually divided into two different categories.
- Mouthguard – classified as a medical device
- Respiratory protection – classified as personal protective equipment.
Both mouth protections and respiratory protections filter the particles by inhalation or exhalation.⁴
Which mask you should use depends on the purpose and occasion. Simply explained, the respiratory protection is a tool to protect yourself against infectious particles in the environment, these are classified as Personal Protective Equipment (PPE) and filters via inhalation.⁴
The mouthguard (also called face mask) aims to reduce the transmission of infectious particles from the user to the environment through exhalation.⁴
However, not all respiratory protections are intended to protect against viruses and bacteria.⁵
Respiratory protections are divided into 3 different classes according to degree of filtration; FFP1, FFP2 and FFP3.⁵
The most common respiratory protections FFP1 and FFTP2 protects against larger particles such as certain types of dust, smoke and aerosols and are not intended to protect against viruses and bacteria. The only respiratory protection intended for protection against viruses and bacteria is FFTP3, the highest class of filters. These can only leak 5% at most and are often used in the chemical industry.⁵
Years of product development resulted in a patented design that:
- Reduces viruses
- Reduces bacteria
- Is easy to breathe through
- Is discreet and comfortable
- Innovative design
- Use up to 8 hours
Not sure how to place NOSA microbial control in your nose correctly?
Watch the instruction video here!
Hold the product bracket with both hands between your index finger and thumb and carefully place the product in your nostrils until the bracket meets the wall.
Carefully press the product upwards with your index finger and thumb until it is placed correctly and does not fall out.
If you feel that the product is placed wrong, try to adjust the product again until it feels comfortable. Do not use if any discomfort arises.
Why NOSA microbial control?
A reduced exposure of viruses and bacteria has been shown to reduce the risk of respiratory infections.
¹ vårdhandboken, 2019
² folkhälsomyndigheten, 2022
³ Sungnak et al, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nature Medicin 26, s.681–687 (2020)
⁴ Läkemedelsverket, 2021
⁵ Europeiska Kommissionen, 2022